Supplementary Figure S1 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

Chand, Dhan; Savitsky, David A.; Krishnan, Shanmugarajan; Mednick, Gabriel; Delepine, Chloe; Garcia-Broncano, Pilar; Soh, Kah Teong; Wu, Wei; Wilkens, Margaret K.; Udartseva, Olga; Vincent, Sylvia; Joshi, Bishnu; Keith, Justin G.; Manrique, Mariana; Marques, Marilyn; Tanne, Antoine; Levey, Daniel L.; Han, Haiyong; Ng, Serina; Ridpath, Jackson; Huber, Olivia; Morin, Benjamin; Galand, Claire; Bourdelais, Sean; Gombos, Randi B.; Ward, Rebecca; Qin, Yu; Waight, Jeremy D.; Costa, Matthew R.; Sebastian-Yague, Alvaro; Rudqvist, Nils-Petter; Pupecka-Swider, Malgorzata; Venkatraman, Vignesh; Slee, Andrew; Patel, Jaymin M.; Grossman, Joseph E.; Wilson, Nicholas S.; Von Hoff, Daniel D.; Stebbing, Justin; Curiel, Tyler J.; Buell, Jennifer S.; O’Day, Steven J.; Stein, Robert B.

doi:10.1158/2159-8290.27938694

Supplementary Figure S1 from Botensilimab, an Fc-Enhanced Anti–CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy

journal contribution

posted on 2024-12-02, 08:41 authored by Dhan Chand, David A. Savitsky, Shanmugarajan Krishnan, Gabriel Mednick, Chloe Delepine, Pilar Garcia-Broncano, Kah Teong Soh, Wei Wu, Margaret K. Wilkens, Olga Udartseva, Sylvia Vincent, Bishnu Joshi, Justin G. Keith, Mariana Manrique, Marilyn Marques, Antoine Tanne, Daniel L. Levey, Haiyong Han, Serina Ng, Jackson Ridpath, Olivia Huber, Benjamin Morin, Claire Galand, Sean Bourdelais, Randi B. Gombos, Rebecca Ward, Yu Qin, Jeremy D. Waight, Matthew R. Costa, Alvaro Sebastian-Yague, Nils-Petter Rudqvist, Malgorzata Pupecka-Swider, Vignesh Venkatraman, Andrew Slee, Jaymin M. Patel, Joseph E. Grossman, Nicholas S. Wilson, Daniel D. Von Hoff, Justin Stebbing, Tyler J. Curiel, Jennifer S. Buell, Steven J. O’Day, Robert B. Stein

This dataset presents the binding characteristics of the mouse anti-CTLA-4 (αCTLA-4) antibodies to various mouse Fc gamma receptors (FcγRs). This information is crucial for understanding the Fc-mediated effector functions of the αCTLA-4 antibodies used in the study. The binding data help explain the mechanisms of action and potential efficacy differences between the various αCTLA-4 antibodies in mouse models.

History

ARTICLE ABSTRACT

This study reveals that Fc-enhanced anti–CTLA-4 harnesses novel mechanisms to overcome the limitations of conventional anti–CTLA-4, effectively treating poorly immunogenic and treatment-refractory cancers. Our findings support the development of a new class of immuno-oncology agents, capable of extending clinical benefit to patients with cancers resistant to current immunotherapies.